State Street® SPDR® MSCI World Health Care UCITS ETF
The State Street® SPDR® MSCI World Health Care UCITS ETF is an exchange-traded index fund (ETF) from SPDR that tracks the MSCI World Health Care index physically. With a total expense ratio (TER) of 0.30% per year it is in the mid cost range for its category. Income is automatically reinvested (accumulating); it trades as a Europe-domiciled UCITS fund. The fund spreads across 110 individual holdings – the largest currently Eli Lilly at 12.41%. The full composition plus the sector and country breakdown are shown below; it is one of 104 ETFs we cover.
The ten largest holdings make up 49.3% of the fund, out of 110 in total. The largest sector is Health Care at 100.0% (as of Oct 30, 2026).
Alysly Data Analysis: SPFS
Data Points
The map shows how SPFS connects to ETFs, indices and other names. Each link is based on measured data and is not a recommendation.
- Amgen Stock · holds
- Bristol-Myers Squibb Company Stock · holds
- Gilead Sciences Stock · holds
- Glaxosmithkline Stock · holds
- Johnson & Johnson Stock · holds
- Novartis Stock · holds
- Roche Holding Ltd Stock · holds
- Vertex Pharmaceuticals Incorporated Stock · holds
- 2B7K ETF · overlaps with
- XMEU ETF · overlaps with
- XSX6 ETF · overlaps with
- XIEE ETF · overlaps with
- XSX7 ETF · overlaps with
- MSCI World Health Care Index · tracks
The 100 Largest Holdings
of 110 in total · as of Oct 30, 2026
Top Sectors
Geographic Breakdown
Holdings lists from our database since Sep 30, 2026, 2 reporting dates.
Changes in Holdings
This compares the holdings list of Sep 30, 2026 with that of Oct 30, 2026: 0 names were added and 0 dropped out. Weights also shift without any buying or selling, because the prices of the holdings move differently.
Weight Up
- Roche Holding Ltd · 3.93% (+3.78 pp)
- Eli Lilly and Company · 12.41% (+1.28 pp)
- AbbVie Inc. · 5.70% (+0.15 pp)
- AstraZeneca PLC · 3.09% (+0.13 pp)
- Genmab A/S · 0.39% (+0.13 pp)
Weight Down
- Johnson & Johnson · 7.20% (-0.46 pp)
- Merck & Co. Inc. · 4.04% (-0.27 pp)
- Thermo Fisher Scientific Inc. · 2.84% (-0.18 pp)
- Alnylam Pharmaceuticals Inc · 0.24% (-0.15 pp)
- Bristol-Myers Squibb Company · 1.40% (-0.13 pp)
Compared With Other Funds
How much this fund overlaps with others — the figure is the share of capital financing the same companies in both.
Data and Charts: SPFS
Effective means the number of equally weighted holdings that would produce the same spread as this fund's 110 counted positions.
Key Facts
| Inception | Feb 28, 2009 |
|---|---|
| Fund size | 804 M |
| Distribution | Accumulating |
| Product structure | Physical |
NAV History
The chart shows net asset value per share and is set to the current year by default. The NAV is up 15.5% year to date and up 23.8% over twelve months. The last recorded close on October 30, 2026, was at 100% of the 52-week range.
Net asset value per share in USD, set once per trading day. It is not an exchange price. Distributions are not added back, so for distributing funds the value drops by the amount paid out on the distribution date.
Net asset values from our database since Apr 29, 2016, 2,689 daily values.
Performance
Calculated from the fund's NAV history.
| Trailing (1Y) | +23.8% | Year to date | +15.5% |
|---|---|---|---|
| Calendar year 2017 | +19.7% | ||
| Calendar year 2018 | +2.5% | ||
| Calendar year 2019 | +23.3% | ||
| Calendar year 2020 | +13.3% | ||
| Calendar year 2021 | +19.6% | ||
| Calendar year 2022 | -5.6% | ||
| Calendar year 2023 | +3.6% | ||
| Calendar year 2024 | +1.0% | ||
| Calendar year 2025 | +14.8% |
Published Fund Performance
| Year to date | +5.19% |
|---|---|
| 1 year annualized | +16.31% |
| 3 years annualized | +8.87% |
| 5 years annualized | +5.19% |
| 10 years annualized | +8.76% |
Periods of one year or longer are annualized, as of Sep 30, 2026.
Fundamental Analysis: SPFS
Tax (Germany)
Equity ETF: 30% partial exemption (Teilfreistellung). Accumulating → Vorabpauschale advance tax applies. Details.